GlassScriptPhysician profile
Jeffrey J Baird
NPI 1588686026
$6,198.15
in general payments reported to CMS, 2019-2025
43 companies · $1,084 in 2025
The $1,084 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $685 · 2020: $571 · 2021: $964 · 2022: $610 · 2023: $811 · 2024: $1,474 · 2025: $1,084.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,344 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,343.84 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,003.29 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $588.79 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Amgen INC. | $521.52 | 2019-2025 | Repatha, Otezla, Repatha |
| Novo Nordisk INC | $450.06 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Takeda Pharmaceuticals U.S.A., INC. | $418.60 | 2019-2024 | Trintellix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $380.66 | 2019-2025 | Jardiance |
| Pfizer INC. | $298.14 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $194.87 | 2019-2022 | |
| Currax Pharmaceuticals LLC | $172.69 | 2022-2025 | Contrave, Nexletol, Nexlizet |
| Biohaven Pharmaceutical Holding Company LTD. | $167.67 | 2022 | |
| Allergan, INC. | $158.90 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $158.31 | 2020-2025 | Xifaxan |
| Biohaven Pharmaceuticals, INC. | $155.58 | 2020-2021 | |
| Sanofi Pasteur INC. | $125.05 | 2019-2023 | |
| Glaxosmithkline, LLC. | $110.92 | 2019-2024 | Shingrix |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Baird listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.